Clinical Trial Update: A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) [Phase 2]

View source ↗

Summary

A Phase II platform trial evaluating cemiplimab alone or with fianlimab, or other novel combinations, for colorectal cancer with minimal residual disease after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Colo-rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING